Lixte Biotechnology Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lixte Biotechnology Holdings generated cash of -$4,293,265, which is more than the previous year. Cash used in financing activities reached the amount of $3,143,361 last year. Net change in cash is therefore -$1,149,904.
Cash Flow
| 2014 | -1.63M | -207.56K | 1.41M |
|---|---|---|---|
| 2015 | -2.18M | 109.60K | 2.05M |
| 2016 | -1.67M | 104.09K | 1.74M |
| 2017 | -1.41M | 0 | 2.51M |
| 2018 | -1.51M | 0 | 4.47M |
| 2019 | -1.67M | 0 | 0 |
| 2020 | -2.13M | 0 | 4.60M |
| 2021 | -4.14M | 0 | 3.89M |
| 2022 | -4.61M | 5.14M | 5.14M |
| 2023 | -4.29M | 0 | 3.14M |
LIXTW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.35M | 4.82M | 5.06M | 2.59M | 4.27M | 1.30M | 199.92K | 25.28K | 44.41K | 475.01K |
Operating activities | ||||||||||
Net income | -5.08M | -6.31M | -6.72M | -3.26M | -2.44M | -2.13M | -1.80M | -2.13M | -2.85M | -2.76M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 773.20K | 1.54M | 2.59M | 1.25M | 748.65K | 0 | 70.69K | 287.15K | 549.69K | 946.17K |
| Deferred income tax benefit | 773.20K | 1.54M | 2.59M | 1.25M | 748.65K | 0 | 70.69K | 287.15K | 549.69K | 946.17K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 14.36K | -14.36K | 0 | 0 | 200K | -200K | 0 |
Inventories | 0 | 0 | 0 | -14.36K | 14.36K | 0 | 0 | 35.11K | 12.59K | 0 |
Accounts payable | -73.97K | 3.79K | 35.67K | 46.74K | -51.66K | -116.82K | 152.43K | 519 | 36.54K | 14.76K |
Cash generated by operating activities | -4.29M | -4.61M | -4.14M | -2.13M | -1.67M | -1.51M | -1.41M | -1.67M | -2.18M | -1.63M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -207.56K |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 5.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 5.14M | 0 | 0 | 0 | 0 | 0 | 104.09K | 109.60K | -207.56K |
Financing activities | ||||||||||
Common Stock Issued | 3.13M | 5.14M | 3.89M | 4.60M | 0 | 4.5M | 2.5M | 1.75M | 1.75M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2K | -2K | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -24.70K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 3.14M | 5.14M | 3.89M | 4.60M | 0 | 4.47M | 2.51M | 1.74M | 2.05M | 1.41M |
Net Change In Cash | -1.14M | 529.64K | -245.52K | 2.47M | -1.67M | 2.96M | 1.10M | 174.64K | -19.13K | -430.60K |
Cash at end of period | 4.20M | 5.35M | 4.82M | 5.06M | 2.59M | 4.27M | 1.30M | 199.92K | 25.28K | 44.41K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |